The present study investigates the potential of a new therapeutic approach in lupus nephritis
combining rituximab (anti-CD20) and belimumab (anti-BAFF). The main goal of the study is to
assess the reduction (and seroconversion) of pathogenic autoantibodies, to evaluate clinical
improvement and assess the safety and feasibility of long-term B-cell depletion.
Phase:
Phase 2
Details
Lead Sponsor:
Leiden University Medical Center
Collaborators:
Dutch Kidney Foundation ZonMw: The Netherlands Organisation for Health Research and Development